|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01/09/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 01/01/2023 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 04/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 26/08/2016 |
Günter von Au
CHM | Chairman | 75 | 27/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| -0.89% | -1.09% | +20.02% | +71.25% | 48.63B | ||
| -1.72% | -1.15% | +47.28% | +115.51% | 41.33B | ||
| -2.01% | -5.96% | +10.68% | +80.50% | 12.06B | ||
| -0.70% | -2.70% | -12.22% | +11.80% | 11.92B | ||
| +0.57% | -0.56% | +26.56% | +153.11% | 9.15B | ||
| -0.31% | -4.34% | +22.63% | +43.23% | 7.49B | ||
| -0.89% | -3.09% | +22.42% | +220.05% | 7.34B | ||
| -1.67% | -0.35% | +41.04% | -12.04% | 7.52B | ||
| +0.03% | -2.72% | -42.28% | +14.39% | 5.19B | ||
| Average | -0.72% | -1.10% | +15.12% | +77.53% | 15.64B | |
| Weighted average by Cap. | -1.02% | -0.48% | +23.75% | +84.15% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















